Story perspectives

Chinese Firms Rush to Supply Generic Wegovy Amid Shortages

9/3/2025

Summary

Story summary

Chinese companies are producing generic versions of Wegovy, supplying over a billion doses of weight-loss drugs in the U.S.
Regulatory restrictions are limiting the availability of these generics, affecting shipments from China.
The FDA reports unprecedented demand for weight-loss drugs, with compounding pharmacies addressing shortages.
As patents expire, Chinese firms are targeting generic semaglutide markets in Canada and Brazil, though growth may slow.
Novo Nordisk's stock has declined significantly, leading to leadership changes and a focus on older drugs like liraglutide.

1 of 1

Story summary

Chinese companies are producing generic versions of Wegovy, supplying over a billion doses of weight-loss drugs in the U.S.
Regulatory restrictions are limiting the availability of these generics, affecting shipments from China.
The FDA reports unprecedented demand for weight-loss drugs, with compounding pharmacies addressing shortages.
As patents expire, Chinese firms are targeting generic semaglutide markets in Canada and Brazil, though growth may slow.
Novo Nordisk's stock has declined significantly, leading to leadership changes and a focus on older drugs like liraglutide.